Assess whether the 505(b)(2) bridge is legally and scientifically enough

SITUATION A boxed-warning proposal from the review division put inspection-readiness findings at a CMO in front of clinical-development physician in a biologics company planning a biosimilar pathway. This Pharma & Life Sciences / Clinical and Evidence Strategy decision is the 505(b)(2) bridge is from inspection-readiness findings at a CMO, and the live options are Proceed under protocol, Pause the pathway, Escalate safety review.

DECISION Clinical-development physician in a biologics company planning a biosimilar pathway must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using inspection-readiness findings at a CMO after a boxed-warning proposal from the review division.

HYPOTHESES TO TEST 1. Authorize Proceed under protocol now; inspection-readiness findings at a CMO already has the discriminator after a boxed-warning proposal from the review division. 2. Keep Pause the pathway in force until inspection-readiness findings at a CMO is completed after a boxed-warning proposal from the review division for clinical-development physician. 3. Treat inspection-readiness findings at a CMO as Escalate safety review because both readings appear after a boxed-warning proposal from the review division. 4. Refuse a Pharma & Life Sciences close: clinical-development physician does not have the decision the 505(b)(2) bridge is turns on in inspection-readiness findings at a CMO.

ANALYSIS REQUIRED 1. Map FDA-response timing and owner in a biologics company planning a biosimilar pathway. 2. Trace CMC, labeling, or pharmacovigilance facts in inspection-readiness findings at a CMO after a boxed-warning proposal from the review division. 3. Separate an isolated adverse event from a systemic quality issue. 4. For this Pharma & Life Sciences Clinical and Evidence Strategy file, read inspection-readiness findings at a CMO against a boxed-warning proposal from the review division and write the one fact that would move the 505(b)(2) bridge is for clinical-development physician.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (inspection-readiness findings at a CMO after a boxed-warning proposal from the review division). Lead with the Pharma & Life Sciences option inspection-readiness findings at a CMO can support after a boxed-warning proposal from the review division, then the two facts that force it, then the Monday action for clinical-development physician in a biologics company planning a biosimilar pathway.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on the 505(b)(2) bridge is, then the evidence in inspection-readiness findings at a CMO, then the action for clinical-development physician - Hypothesis scorecard against inspection-readiness findings at a CMO: supported / rejected / untestable - Clinical and Evidence Strategy finding in inspection-readiness findings at a CMO that a second reviewer can re-perform - Missing page in inspection-readiness findings at a CMO after a boxed-warning proposal from the review division, if any